VOYA Investment Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-18,274
Closed -$33.8K 3065
2023
Q1
$33.8K Sell
18,274
-137,386
-88% -$170K ﹤0.01% 2839
2022
Q4
$173K Buy
155,660
+95,730
+160% +$136K ﹤0.01% 2623
2022
Q3
$140K Buy
59,930
+7,552
+14% +$26.7K ﹤0.01% 2703
2022
Q2
$159K Buy
52,378
+20,734
+66% +$101K ﹤0.01% 2481
2022
Q1
$215K Sell
31,644
-251
-0.8% -$1.79K ﹤0.01% 2331
2021
Q4
$266K Sell
31,895
-105
-0.3% -$865 ﹤0.01% 2368
2021
Q3
$238K Buy
32,000
+307
+1% +$1.9K ﹤0.01% 2478
2021
Q2
$216K Buy
31,693
+12,171
+62% +$101K ﹤0.01% 2560
2021
Q1
$200K Buy
+19,522
New +$214K ﹤0.01% 2548

Other funds holding JNCE

VOYA Investment Management's JNCE Position: Q2 2023 in Review

VOYA Investment Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 18,274 shares — an estimated $33.8K sold.

VOYA Investment Management first reported a position in JNCE in Q1 2021 and held it in 9 quarters. The position peaked at $266K in Q4 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

  • VOYA Investment Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • VOYA Investment Management sold 18,274 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $33.8K.
  • VOYA Investment Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
  • VOYA Investment Management's Jounce Therapeutics, Inc. Common Stock position peaked at $266K in Q4 2021.
  • 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on VOYA Investment Management's 13F filing for Q2 2023, filed 14 Aug 2023.